&w=3840&q=100)
AstraZeneca Pharma rises 2% on securing CDSCO nod for Benralizumab solution
AstraZeneca Pharma share price: Pharmaceutical company AstraZeneca shares rose as much as 2.14 per cent to hit an intraday high of ₹8,089 per share on the last trading day of the week i.e. Friday, May 30, 2025.
At 1:30 PM, AstraZeneca Pharma shares were trading 1.26 per cent higher at ₹8,018.90 per share. By comparison, the BSE Sensex was trading 0.21 per cent lower at 81,461.57 levels.
Why did AstraZeneca share price rise in trade today?
AstraZeneca Pharma share price rose after it received approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import for sale and distribution of Benralizumab 30 mg/ml solution for injection (brand name: Fasenra) for an additional indication.
In an exchange filing, AstraZeneca Pharma said, 'This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) for an additional indication.'
Benralizumab is used as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
Besides, the approval also paves way for the marketing of Benralizumab 30 mg/ml solution for injection (Brand name: Fasenra) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
Earlier this week, AstraZeneca Pharma India secured approval from CDSCO to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication.
Osimertinib as monotherapy is used in the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, and whose disease has not progressed during or following platinum-based chemoradiation therapy
AstraZeneca Pharma Q4 results
The Board of Directors of AstraZeneca Pharma will meet today to consider and approve the March quarter of financial year 2025 (Q4FY25) and financial year 2025 (FY25) results, along with dividend for FY25, if any.
About AstraZeneca Pharma
AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group.
The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid-19 vaccine
Leveraging data science and artificial intelligence (AI), AstraZeneca claims to boost the success rates and efficiency of its research and development (R&D) processes.
The market capitalisation of AstraZeneca Pharma is ₹20,037.38 crore, according to BSE. The company falls under the BSE500 index. The 52-week high of AstraZeneca share price is ₹9,199, while its 52-week low is ₹5,415.55.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
5 hours ago
- The Print
Adani Group stocks decline; Adani Ports fall over 2 pc
In a stock exchange filing, the group said reports of links between any of its entities and Iranian LPG are 'baseless and mischievous'. Adani Group on Monday said it does not handle any cargo coming from Iran or any Iranian-owned ship at any of its ports, as it denied any deliberate engagement in sanctions evasion. New Delhi, Jun 3 (PTI) Adani Group stocks ended lower on Tuesday, with Adani Ports, NDTV and Adani Energy falling over 2 per cent each. The filing was in response to a Wall Street Journal (WSJ) report that said US prosecutors were investigating if Adani group companies imported Iranian LPG into India through their Mundra port in Gujarat. Shares of Adani Ports dropped 2.42 per cent, NDTV fell by 2.25 per cent, Adani Energy Solutions declined 2.18 per cent, Adani Power skidded 2.02 per cent and Adani Enterprises went lower by 1.89 per cent on the BSE. The stocks of Adani Total Gas edged lower by 1.62 per cent, Adani Green slipped 1.58 per cent, Sanghi Industries Ltd (1.16 per cent), Ambuja Cements (0.88 per cent), ACC (0.22 per cent) and AWL Agri Business (0.06 per cent). In intra-day trade, NDTV tanked 4.92 per cent, Sanghi Industries dropped 3.44 per cent, Adani Ports fell by 2.77 per cent, Adani Power lost 2.69 per cent, Adani Enterprises went lower by 2.63 per cent, Adani Energy (2.35 per cent), Adani Total (2.10 per cent), Adani Green (2 per cent), Ambuja Cements (1.21 per cent), AWL Agri (1.14 per cent) and ACC (0.62 per cent). In the equity market, the 30-share BSE Sensex tanked 636.24 points or 0.78 per cent to settle at 80,737.51. The NSE Nifty plunged 174.10 points or 0.70 per cent to 24,542.50. 'By policy, the Adani Group does not handle any cargo from Iran at any of our ports. This includes any shipments originating from Iran or any vessels operating under the Iranian flag,' the conglomerate said in the filing. It went on to state that the group 'does not manage or facilitate any ships whose owners are Iranian. This policy is strictly adhered to across all our ports'. The WSJ report claimed that its investigation had found tankers travelling between Mundra and the Persian Gulf exhibited traits experts say are common for ships evading sanctions. Purchase of Iranian oil or products is sanctioned over Tehran's suspected nuclear programme. Calling the report 'baseless and mischievous', the Adani group said it 'categorically denies any deliberate engagement in sanctions evasion or trade involving Iranian-origin LPG'. It went on to add that it was 'not aware of any investigation by US authorities on this subject'. The report, it said, 'appears to be based entirely on incorrect assumptions and speculation'. PTI SUM DR This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Business Standard
6 hours ago
- Business Standard
INR stays under pressure amid dollar strength, higher oil prices
The Indian rupee declined 21 paise to settle at 85.60 (provisional) against the US dollar on Tuesday, weighed down by a firm American currency and outflow of foreign funds. Traders would likely observe the release of the JOLTS Job Openings later on Tuesday. The local unit remained under pressure tracking negative domestic equity markets amid geopolitical uncertainties. Indian shares fell sharply on Tuesday, extending losses for a third straight session due to heightened geopolitical and trade tensions. Rising oil prices remained a concern after a second round of direct peace talks between Russia and Ukraine have ended without a major breakthrough and reports suggested that Iran is set to reject a U.S. nuclear deal proposal that would be key to easing sanctions on the major oil producer. The benchmark 30-share BSE Sensex fell 636.24 points, or 0.78 percent, to 80,737.51 while the broader NSE Nifty index closed at 24,542.50, down 174.10 points, or 0.70 percent, from its previous close. Investors are also awaiting cues from the Reserve Bank's monetary policy announcements. RBI's Monetary Policy Committee (MPC) will begin deliberations on its bi-monthly policy on Wednesday and the outcome is scheduled to be announced on June 6.
New Indian Express
9 hours ago
- New Indian Express
Market slumps for third straight session amid global uncertainty, profit booking
India's equity markets extended their decline for a third consecutive session on Tuesday, dragged down by broad-based selling pressure and profit booking at elevated levels. Weak global cues, lingering geopolitical tensions, and currency market volatility-fuelled by a softening US dollar-further dampened investor sentiment, deepening the downturn. Despite a positive opening, market sentiment turned weak in the second half. The Nifty 50, after hitting an intraday high of 24,845, settled at 24,542.50, down 174 points or 0.70%, from the previous day's closing. The BSE Sensex mirrored similar trends, closing the day with a loss of 636 points, or 0.78%, at 80,737.51. The benchmarks have fallen by about 1.4% each in the past three sessions. The broader indices showed a mixed trend — the smallcap index closed almost flat, while the midcap index lost nearly half a per cent. Sectorally, most indices closed in the red. The Nifty Realty index was the outlier, gaining 1%, supported by continued investor interest in housing and commercial real estate segments amid favourable demand dynamics. Vinod Nair, Head of Research, Geojit Investments, said that profit booking is evident across sectors, except for real estate stocks, supported by expectations of an interest rate cut by the RBI. 'Mid- and small-cap stocks are experiencing relatively less consolidation than large caps due to better earnings growth & moderation in premium valuation. While short-term consolidation is likely to persist, strong domestic oriented players are estimated to provide outperformance against external volatility,' added Nair.
